{"entity":{"type":"insider","cik":"0001492749","url":"/insider/0001492749","json_url":"/insider/0001492749.json","name":"Reid Laurence","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":16,"n_filings":9,"first":"2012-02-23","last":"2021-09-17","span_basis":"filed_date"},"name_variants":[{"name":"Reid Laurence","source":"filing","n_filings":9,"first_seen":"2012-02-23","last_seen":"2021-09-17"}],"transactions":[{"id":5276804,"accession":"0000899243-21-036500","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-036500","line_url":"/filing/0000899243-21-036500#line-1","is_derivative":false,"issuer_cik":"0001492749","issuer_name":"Decibel Therapeutics, Inc.","issuer_ticker":"DBTX","issuer_name_source":null,"issuer_url":"/issuer/0001492749","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Director, Officer (President and Chief Executive)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and Chief Executive","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":7.64,"price_display":"7.64","price_state":"stated","total_value":76400.0,"total_display":"76,400.00","total_whole":"76,400","shares_owned_after":25849.0,"shares_owned_after_display":"25,849","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-15","filed_date":"2021-09-17","scope":"insider"},{"id":6467960,"accession":"0001553878-14-000022","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001553878-14-000022","line_url":"/filing/0001553878-14-000022","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":90.66697013,"price_display":"90.67","price_state":"stated","total_value":906669.7013,"total_display":"906,669.70","total_whole":"906,670","shares_owned_after":8492.0,"shares_owned_after_display":"8,492","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-18","filed_date":"2014-11-19","scope":"insider","n_lines":3},{"id":6387712,"accession":"0001553878-14-000008","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001553878-14-000008","line_url":"/filing/0001553878-14-000008","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13500.0,"shares_display":"13,500","price_per_share":67.33552592592592,"price_display":"67.34","price_state":"stated","total_value":909029.6,"total_display":"909,029.60","total_whole":"909,030","shares_owned_after":3905.0,"shares_owned_after_display":"3,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-08-18","filed_date":"2014-08-20","scope":"insider","n_lines":2},{"id":6241722,"accession":"0001325812-14-000029","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001325812-14-000029","line_url":"/filing/0001325812-14-000029","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13500.0,"shares_display":"13,500","price_per_share":57.828465925925926,"price_display":"57.83","price_state":"stated","total_value":780684.29,"total_display":"780,684.29","total_whole":"780,684","shares_owned_after":3905.0,"shares_owned_after_display":"3,905","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-05-19","filed_date":"2014-05-21","scope":"insider","n_lines":2},{"id":6349973,"accession":"0001325812-14-000023","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001325812-14-000023","line_url":"/filing/0001325812-14-000023","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":20400.0,"shares_display":"20,400","price_per_share":80.06077134803921,"price_display":"80.06","price_state":"stated","total_value":1633239.7355,"total_display":"1,633,239.74","total_whole":"1,633,240","shares_owned_after":9761.0,"shares_owned_after_display":"9,761","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-02-19","filed_date":"2014-02-20","scope":"insider","n_lines":4},{"id":4616307,"accession":"0001553878-13-000028","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001553878-13-000028","line_url":"/filing/0001553878-13-000028#line-2","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13500.0,"shares_display":"13,500","price_per_share":53.3557,"price_display":"53.36","price_state":"stated","total_value":720301.95,"total_display":"720,301.95","total_whole":"720,302","shares_owned_after":11681.0,"shares_owned_after_display":"11,681","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-13","filed_date":"2013-11-15","scope":"insider"},{"id":4563693,"accession":"0001553878-13-000006","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001553878-13-000006","line_url":"/filing/0001553878-13-000006#line-2","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP and Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP and Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP and Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":150000.0,"total_display":"150,000.00","total_whole":"150,000","shares_owned_after":11681.0,"shares_owned_after_display":"11,681","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-28","filed_date":"2013-05-30","scope":"insider"},{"id":5558517,"accession":"0001553878-13-000001","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001553878-13-000001","line_url":"/filing/0001553878-13-000001#line-2","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":125000.0,"total_display":"125,000.00","total_whole":"125,000","shares_owned_after":11681.0,"shares_owned_after_display":"11,681","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-02-08","filed_date":"2013-02-12","scope":"insider"},{"id":2510551,"accession":"0001325812-12-000008","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001325812-12-000008","line_url":"/filing/0001325812-12-000008#line-1","is_derivative":false,"issuer_cik":"0001178670","issuer_name":"ALNYLAM PHARMACEUTICALS, INC.","issuer_ticker":"ALNY","issuer_name_source":null,"issuer_url":"/issuer/0001178670","owner_cik":"0001492749","owner_name":"Reid Laurence","owner_display_name":"Reid Laurence","owner_url":"/insider/0001492749","role":"Officer (SVP, Chief Business Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Business Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Business Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":930.0,"shares_display":"930","price_per_share":10.75,"price_display":"10.75","price_state":"stated","total_value":9997.5,"total_display":"9,997.50","total_whole":"9,998","shares_owned_after":11681.0,"shares_owned_after_display":"11,681","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-02-21","filed_date":"2012-02-23","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":16,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":14,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":16},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001656536","name":"Decibel Therapeutics, Inc.","url":"/issuer/0001656536","role":"Director, Officer (President and Chief Executive)","n_filings":1,"first_seen":"2021-09-17","last_seen":"2021-09-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001178670","name":"ALNYLAM PHARMACEUTICALS, INC.","url":"/issuer/0001178670","role":"Officer (SVP, Chief Business Officer)","n_filings":8,"first_seen":"2012-02-23","last_seen":"2014-11-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001492749","retrieved_at":"2026-08-27T16:45:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}